I think the most interesting question here is: does UK AISI's loss of access portend limited commercial model access for non-US customers? Could European pharma firms be withheld BioMythos access while US firms develop next-gen drugs? I think yes. Commercial frontier access is very costly to sustain; first for misuse and distillation concerns, eventually also for shortages in inference compute. The question is who makes the cut. The hope was that US allies - in particular the UK - could just…

FT@FT14h ago

The company’s newly launched Claude Mythos 5.1 was only made available to vetted US organisations, excluding for the first time the UK’s AI Security Institute, the global leader in the testing of frontier AI models. https://t.co/RlwUnHsY62 https://t.co/Qls6UJSdx1